ThitareeSarmkasat/iStock via Getty Images
Overview
Zogenix (ZGNX) is developing Fintepla (low-dose fenfluramine) for the treatment of rare and serious pediatric seizures. Fintepla was FDA-approved last June for the treatment of Dravet syndrome
Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In
Share this article
More News
US political impasse leaves banks on crypto sidelines
March 5, 2026
crypto kiosk regulations
March 5, 2026
